echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Jinlida protects pancreatic β-cells, promotes insulin secretion, improves glucose metabolism disorders, reduces diabetic microvascular damage

    Jinlida protects pancreatic β-cells, promotes insulin secretion, improves glucose metabolism disorders, reduces diabetic microvascular damage

    • Last Update: 2021-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ,。

    ,,9《 (IDF Diabetes Atlas)》,20~794.


     

    Diabetes is a metabolic disease, and its pathogenesis is impaired pancreatic islet function and insulin resistance in the patient's body, which in turn causes an increase in blood sugar in the body.


    Medical screening

    As the current population aging in China continues to increase, coupled with the long-term prevalence of diabetes, large blood vessels and capillaries are damaged and complications such as heart, brain, kidney, peripheral nerves, eyes, feet and other organs are endangered.


    Vascular management

    The importance of early screening and early prevention

    The importance of early screening and early prevention

    For patients who have been diagnosed with diabetes, it is necessary to correct metabolic disorders, protect pancreatic islet function, and avoid complications through effective treatment.


           

           Clinical rational use of drugs and new progress in scientific research

           Clinical rational use of drugs and new progress in scientific research

           In order to deal with the harm caused by diabetes and its complications, my country's scientific research team has also been seeking new treatment concepts and clinical drugs to expand diabetes prevention strategies and options.


    The mechanism of Jinlida granule on the prevention and treatment of diabetes and its complications is to apply the theory of traditional Chinese medicine.


    The model of type 1 diabetes and type 2 diabetes rats was constructed, and the effect of Jinlida granule on glucose metabolism in diabetic rats was observed.


    Metformin Immunization

          Experimental results show that Jinlida can effectively improve the morphology and number of pancreatic tissue cells in diabetic rats; effectively improve the area of ​​insulin immunopositive staining; effectively improve the oxidative stress state of pancreatic tissue in diabetic rats; and can effectively improve pancreatic tissue inflammation in diabetic rats Factor indicators.


           In the study of Jinlida's effect on diabetic microvascular disease and its mechanism, Professor Zou Junjie's research team established a rat model of diabetic microvascular disease to observe the changes in the common pathology and ultrastructure of the diseased tissue and the changes after drug intervention.


           Studies have found that Jinlida has a protective effect on the kidneys of diabetic rats and can improve hippocampal cell apoptosis in diabetic rats; it can effectively reduce the abnormal proliferation of retinal endothelial cells in diabetic rats and inhibit the formation of new blood vessels.


           Through a series of basic experimental studies, the scientific research team of Professor Junjie Zou found that Jinlida granules not only interfere with the blood sugar of type 1 diabetes and type 2 diabetes, but also have an effect on oxidative stress, RAS system, growth hormone, and endocrine system.


    A series of basic experimental studies have found that Jinlida Granules not only interferes with the blood sugar of type 1 diabetes and type 2 diabetes, but also has some effects on oxidative stress, RAS system, growth hormone, endocrine system, and even the central nervous system.


          In the future, it is also hoped that evidence-based medicine research can be conducted through clinical multi-center trials, and more powerful data can be obtained to support and guide clinical medication.


     

     

    Introduction of Professor Junjie Zou:

    Introduction of Professor Junjie Zou:

    Professor, Chief Physician, Doctoral Supervisor; Director of the Department of Endocrinology, Shanghai Changzheng Hospital ; Member of the Diabetes Society of Shanghai Medical Association ; Member of the Receptor and Signal Transduction Professional Committee of the Chinese Pathophysiology Society ; Member of the Microvascular Disease Professional Committee of the PLA ; Shanghai Diabetes Rehabilitation Member of the Association ; Member of the Chinese Internal Medicine Yearbook, Member of the Editor of the Journal of Difficult and Intractable Diseases, Member of the Editor of the Journal of Clinical and Military Medicine ; Visiting Scholar of the Pittsburgh Medical College , USA.


    ; ; ; ; ; ;

    Mainly engaged in basic and clinical research on chronic complications of diabetes and thyroid disease.


    Natural Science Fund

     

     

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.